Drugs / PBT-434
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05864365 | May 2023 → Feb 2025 | multiple system atrophy | Alterity Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05109091 | Jul 2022 → Nov 2024 | multiple system atrophy | Alterity Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07531433 | — | multiple system atrophy | Alterity Therapeutics | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBT-434 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068541 ↗ |
| Known as | ATH434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07531433 ↗ |
| Modality | Small molecule | — CHEMBL6068541 ↗ |
| Route | Oral | “ATH434 taken by mouth two times per day” NCT05864365 ↗ |